The Worldwide Human Leukocyte Antigen Testing Industry is Expected to Reach $1.1 Billion by 2028 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Human Leukocyte Antigen Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Services, Technology, and End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

The human leukocyte antigen (HLA) market is projected to reach US$ 1,155.65 million by 2028 from US$ 697.74 million in 2021; it is expected to register a CAGR of 7.5% from 2022 to 2028.

The increasing number of plasma donation and organ transplantation procedures and expanding range of applications of HLA testing are driving the market growth. However, errors in accuracy hamper the human leukocyte antigen (HLA) market growth.

Human leukocyte antigens (HLAs) are the specialized proteins present on all cell surfaces of the human body, except red blood cells. HLA testing has significant application in organ transplantation, which can be recommended as a part of the treatment of kidney failure, chronic liver cirrhosis, and chronic heart disease, among other medical issues.

The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing. Before transplantation, HLA testing is performed to check tissue compatibility between patients and donors to avoid graft rejection. In recent years, transplantation has become a successful practice worldwide. According to data published in Global Observatory on Donation and Transplantation (GODT), in 2020, 129,681 organ transplants were recorded in total. Of these, 31.7% were living kidney transplants and 20.40% were living liver transplants.

Governments of various countries are taking initiatives to spread awareness about the need for organ donation and the benefits of organ transplantation in certain treatment procedures. For Instance, the Organ Procurement and Transplantation Network (OPTN) has implemented a few strategies to improve the number of organ transplantation procedures in the US. These strategies focus on increasing the number of organ and tissue transplants among patients with end-stage organ disease, altering the current organ distribution, and modifying the organ transplantation waitlist by redistributing the existing organ soppy.

Furthermore, the OPTN has used out-of-box strategies to improve organ transplantation. These innovative strategies include the optimized use of organs obtained from deceased patients [e.g., donation after cardiac death (DCD) or brain-dead donors], reducing discards of organs, promoting living donation, and improving the rate of potential organ donation authorization. Thus, the growing demand for organ transplantation leads to the requirement of a more substantial number of HLA testing kits and consumables, which drives the growth of the HLA testing market.

Market Dynamics

Drivers

• Increasing Number of Plasma Donation and Organ Transplantation Procedures
• Expanding Range of Applications of HLA Testing

Restraints

• Errors in Accuracy

Opportunities

• Rising Government Funding for Organ Donation

Future Trends

• Technological Advancements in Field of Histocompatibility

Companies Mentioned

• Thermo Fisher Scientific Inc.
• CareDx
• Qiagen
• Illumina Inc.
• Bio-Rad Laboratories, Inc.
• TBG Diagnostics Limited
• F.Hoffmann-La Roche Ltd.
• Takara Bio Inc.
• Luminex Corporation
• Omixon Inc.
• The Sequencing Center
• Protrans
• HistoGenetics LLC

For more information about this report visit https://www.researchandmarkets.com/r/9g5n7o